- Home
- AMSC vs ETNB Comparison
AMSC vs ETNB Comparison
Compare AMSC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSC
- ETNB
- Stock Information
- Founded
- AMSC 1987
- ETNB 2018
- Country
- AMSC United States
- ETNB United States
- Employees
- AMSC N/A
- ETNB N/A
- Industry
- AMSC Metal Fabrications
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- AMSC Consumer Discretionary
- ETNB Health Care
- Exchange
- AMSC Nasdaq
- ETNB Nasdaq
- Market Cap
- AMSC 1.0B
- ETNB 933.6M
- IPO Year
- AMSC 1991
- ETNB 2019
- Fundamental
- Price
- AMSC $26.48
- ETNB $8.01
- Analyst Decision
- AMSC Strong Buy
- ETNB Buy
- Analyst Count
- AMSC 3
- ETNB 7
- Target Price
- AMSC $28.33
- ETNB $30.33
- AVG Volume (30 Days)
- AMSC 1.4M
- ETNB 1.3M
- Earning Date
- AMSC 01-22-2025
- ETNB 11-07-2024
- Dividend Yield
- AMSC N/A
- ETNB N/A
- EPS Growth
- AMSC N/A
- ETNB N/A
- EPS
- AMSC N/A
- ETNB N/A
- Revenue
- AMSC $176,142,000.00
- ETNB N/A
- Revenue This Year
- AMSC $47.52
- ETNB N/A
- Revenue Next Year
- AMSC $18.53
- ETNB N/A
- P/E Ratio
- AMSC N/A
- ETNB N/A
- Revenue Growth
- AMSC 46.93
- ETNB N/A
- 52 Week Low
- AMSC $9.37
- ETNB $6.43
- 52 Week High
- AMSC $38.02
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- AMSC 44.83
- ETNB 48.30
- Support Level
- AMSC $23.57
- ETNB $6.43
- Resistance Level
- AMSC $25.91
- ETNB $8.10
- Average True Range (ATR)
- AMSC 2.29
- ETNB 0.52
- MACD
- AMSC -0.41
- ETNB 0.01
- Stochastic Oscillator
- AMSC 23.70
- ETNB 76.33
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet world's demand for smarter, cleaner and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).